Tetrahydroimidazopyridine derivatives as modulators of TNF activity

Patent metadata

Field	Value
Publication number	US-9969728-B2
Application number	US-201415038239-A
Country	US
Kind code	B2
Filing date	Dec 8, 2014
Priority date	Dec 9, 2013
Publication date	May 15, 2018
Grant date	May 15, 2018

Abstract

A series of substituted 5,6,7,8-tetrahydroimidazo[1,2-α]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

First claim

The invention claimed is:

1. A compound represented by formula (IIA) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof, or a glucuronide derivative thereof, or a co-crystal thereof:

wherein
R 11 represents hydrogen or halogen;
R 12 represents hydrogen or halogen; and
R 15 represents C 1-6 alkyl or difluoromethoxy;
R 16 represents hydrogen or C 1-6 alkyl;
E represents —CH 2 ;
Q represents —CH 2 — or —CH 2 O—;
Z represents (oxo)oxazolidinylphenyl.

2. The compound as claimed in claim 1 wherein R 11 represents hydrogen.

3. The compound as claimed in claim 1 wherein R 12 represents hydrogen or fluoro.

4. The compound as claimed in claim 1 wherein R 15 represents difluoromethoxy.

5. The compound of claim 1 that is
3-{3-[(3-{[2-(Difluoromethoxy)phenyl]methyl}-5,6,7,8-tetrahydroimidazo[1,2-α]pyridin-2-yl)methoxy]phenyl}oxazolidin-2-one; or
3-{3-[(3-{[2-(Difluoromethoxy)phenyl]methyl}-7-floro-5,6,7,8-tetrahydroimidazo[1,2-α]pyridin-2-yl)methoxy]phenyl}oxazolidin-2-one.

6. A pharmaceutical composition comprising a compound according to claim 1 or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof, or a glucuronide derivative thereof, or a co-crystal thereof, in association with a pharmaceutically acceptable carrier.

7. The pharmaceutical composition as claimed in claim 6 further comprising an additional pharmaceutically active ingredient.

Assignees

• Ucb Biopharma Sprl

Inventors

• Defays Sabine
• Heer Jag Paul
• Jackson Victoria Elizabeth
• Johnson James Andrew
• Kroeplien Boris
• Porter John Robert

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title